Copyright
©The Author(s) 2023.
World J Pharmacol. Feb 17, 2023; 12(1): 1-11
Published online Feb 17, 2023. doi: 10.5497/wjp.v12.i1.1
Published online Feb 17, 2023. doi: 10.5497/wjp.v12.i1.1
Variable | mean ± SD | ||
Test (T) | Reference (R1) | Reference (R2) | |
Cmax (ng/mL) | 132.12 (65.31) | 308.57 (173.63) | 136.90 (67.91) |
AUC0-t | 2738.083 (1164.121) | 4953.205 (2472.121) | 3065.766 (1295.989) |
AUC0-inf | 3109.578 (1342.394) | 5744.760 (2917.508) | 3614.170 (1850.356) |
Tmax | 11.45(6.05) | 6.00 (1.49) | 10.85 (6.33) |
Kel | 0.022 (0.007) | 0.021 (0.007) | 0.023 (0.008) |
t1/2 | 34.89 (13.18) | 37.83 (14.95) | 35.16 (20.14) |
Residual area | 11.92 (7.41) | 12.86 (7.86) | 12.22 (9.10) |
- Citation: Naqvi SMH, Gala MYN, Muchhala S, Arumugam A, Panigrahi D, Patil D, Rathod R, Mane A. Pharmacokinetics/Pharmacodynamics study of Fixtral SB as compared to supra bioavailable itraconazole and conventional itraconazole. World J Pharmacol 2023; 12(1): 1-11
- URL: https://www.wjgnet.com/2220-3192/full/v12/i1/1.htm
- DOI: https://dx.doi.org/10.5497/wjp.v12.i1.1